Adult Stem Cells Are Helping Scleroderma Patients PDF Print E-mail
Wednesday, 20 July 2011 22:37
Dr. Richard Burt and colleagues at Northwestern University have just published a new study in The Lancet that provides more evidence for the success of adult stem cell transplant in treating System Sclerosis (Scleroderma).

Ten patients were treated with their own adult stem cells, and all improved at or before 12 months after treatment, compared with zero of the nine patients that received cyclophosphamide, a chemotherapeutic agent considered the “standard of care” for this disease. None of the adult stem cell-treated patients had their disease worsen, while 8 of the 9 chemo-treated patients showed worsening, and eventually 7 of the chemo patients switched to the adult stem cell treatment.

The researchers note that the adult stem cell treatment improves skin and lung function in these patients for up to 2 years (the length of the current study) and is preferable to the current standard of care.

The new report is accompanied by a commentary by Farge and Gluckman that says the Burt et al. study provides “the best data to date for transplantation in Scleroderma”, and “Despite the small number of patients and short follow-up of ASSIST, the findings of this trial are important for patients with systemic sclerosis, the medical community, and policy makers.”

Dr. Burt is featured in a recently-released video discussing his ideas for use of adult stem cells to treat patients with autoimmune diseases. Burt and his team are using this technique to help treat patients suffering from some 23 different diseases, and the techniques he has developed are now being used in treatment centers around the globe.

Adult stem cells are helping patients now.

Source: Prentice, D. (2011), "Adult Stem Cells Helping Patients With Scleroderma Skin Disease"; Lifenews.com; original article can be viewed here.

 
More articles :

» New, Non-invasive Test May Help Diagnose Pulmonary Hypertension in Scleroderma

In patients with Systemic Sclerosis (SSc) – or – a condition called pulmonary hypertension (PH) is a leading cause of death. Having PH means the blood pressure between the heart and lungs is elevated.The Need for New Tests for PH in SScThe...

» The Management and Treatment of Scleroderma is Improving

Management of systemic sclerosis is likely to improve as soon as an ongoing convergence of mechanistic insights, improved understanding of clinical trial design, and interest by industry results in new treatments, according to Dr. Robert F....

» Rituximab Shows Promise in Scleroderma

Rituximab (Rituxan) improved lung function in patients with , a small proof-of-principle study found.At one year, patients randomized to receive rituximab had a median 10.25% increase in forced vital capacity (FVC) compared with baseline, while...

» Stanford Medical Researchers Discover Master Regulator of Skin Development

The surface of your skin, called the , is a complex mixture of many different cell types — each with a very specific job. The production, or differentiation, of such a sophisticated tissue requires an immense amount of coordination at the cellular...

» Researchers Testing Intense Pulsed Light As An Alternative Treatment for Telangiectatases

Telangiectatases are knot-like clusters of blood vessels on the skin which can occur in 30 to 50 per cent of patients with Systemic Sclerosis, also known as . Telangiectases tend to occur on the face, neck, and upper limbs and can cause...

» Small Intestinal Bacterial Overgrowth A Problem For Scleroderma Patients

More than a third of patients with systemic sclerosis and intestinal symptoms have an increase in gastrointestinal tract bacteria, an alteration in the type of gut microbes present, or both, based on data from a French study presented at the annual...